32 results
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
, stockholders holding Shares as part of a straddle, hedging, constructive sale or conversion transaction, stockholders that purchase or sell Shares as part
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
not currently manage its foreign currency exposure through hedging programs and will continue to monitor its foreign currency assets and liabilities and evaluate … purposes. The Company does not currently manage interest rate exposure through hedging programs. The Company will continue to monitor and evaluate the need
8-K
EX-1.1
PNT
POINT Biopharma Global Inc.
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
that the foregoing restrictions preclude the undersigned from engaging in any hedging or other transaction which is designed to or which reasonably could be expected … the undersigned. Such prohibited hedging or other transactions would include without limitation any short sale or any purchase, sale or grant of any right
424B5
37dppm4 db
14 Sep 22
Prospectus supplement for primary offering
4:12pm
424B5
2rm8nsh
13 Sep 22
Prospectus supplement for primary offering
5:19pm
424B3
socda
11 Jul 22
Prospectus supplement
4:32pm
POS AM
b9336xi
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
424B3
0gukh4i8rd3
13 May 22
Prospectus supplement
8:18am
DEF 14A
1m0ceunz ajbhdzi
28 Apr 22
Definitive proxy
8:36am
424B3
rjj6c90lrjkdr
31 Mar 22
Prospectus supplement
11:42am
POS AM
8jk8tsupp0m
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
omnj2gtvdx eifth
12 Nov 21
Prospectus supplement
8:41am
424B3
vfrnfrecb2vl17vkwg6q
13 Aug 21
Prospectus supplement
5:25pm